Financial Profile Improved Markedly with Global License Agreement to Develop and Commercialize Nyxol for All Three Indications with Cash Runway...
Paper highlights efzofitimod as a first-in-class biologic with significant anti-inflammatory propertiesSAN DIEGO, March 30, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma,...
No quantifiable VYN201 plasma concentrations above the assay lower limit of quantification supports “soft” drug approach for topical pan-BD BET...
- Topline data for pivotal Phase 3 trial evaluating brilaroxazine for the treatment of schizophrenia remains on track for mid-2023...
EDMONTON, ALBERTA, CHATHAM, ONTARIO and TEL-AVIV, ISRAEL, March 30, 2023 (GLOBE NEWSWIRE) -- Atlas Global Brands Inc. (“Atlas Global” or...
BOSTON, March 30, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and...
CELEBRATION, Fla., March 30, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics (NasdaqGS: ZVRA) (“Zevra” or the “Company” and formerly KemPharm, Inc.),...
Acquired IXINITY® commercial payment and milestone economics from Aptevo TherapeuticsEMERYVILLE, Calif., March 30, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ:...
Conference Call Scheduled for Today at 8:30 a.m. Eastern TimeBERKELEY HEIGHTS, N.J., March 30, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc....
Call Scheduled for Today, Thursday, March 30, 2023 at 5:00 pm ETLITTLETOWN, Colo., March 30, 2023 (GLOBE NEWSWIRE) -- Vivos...
Please read the announcement in PDF Attachment 2023_51_Novozymes_extraordinary_shareholders_meeting_resolutions
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY (IN WHOLE OR IN PART), IN OR INTO THE UNITED STATES...
Please read the announcement in PDF Attachment 2023_50_Combination_between_Novozymes_and_Chr._Hansen_approved_by_the_Novozymes_shareholders
Brexafemme complements GSK’s industry-leading infectious disease portfolio with an FDA approved treatment for vulvovaginal candidiasisSCYNEXIS will receive an upfront payment...
OLINVYK-treated patients had a statistically significant 1.6 day (~27%) reduction in average overall hospital length of stay compared to matched...
CAMBRIDGE, Mass., March 30, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the...
Industry leader brings more than 25 years of scientific leadership and expertise in T-cell therapy developmentHOUSTON, March 30, 2023 (GLOBE...
- Additional evidence of durable anti-cancer activity with MDNA11 monotherapy seen in latest radiographic scans from first four dose escalation cohorts...
– Initiated registration program for SerpinPC to treat hemophilia B; Enrolling subjects in PRESent-5, observational study – – First subject...
Combined company will pursue late-stage clinical development of oral neflamapimod for the treatment of dementia with Lewy bodies EIP Pharma...